Study of LY3410738 Administered to Patients With Advanced Solid Tumors With IDH1 or IDH2 Mutations
Eli Lilly and Company
Eli Lilly and Company
M.D. Anderson Cancer Center
Solve Therapeutics
Degron Therapeutics Co.
Actym Therapeutics, Inc.
M.D. Anderson Cancer Center
Jonsson Comprehensive Cancer Center
National Cancer Institute (NCI)
MacroGenics
Celgene
Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Memorial Sloan Kettering Cancer Center
Valerio Therapeutics
Valerio Therapeutics
Mannkind Corporation